Indication name: Hunter syndrome
(Mucopolysaccharidosis Type II)
Hunter syndrome (Mucopolysaccharidosis Type II) – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China).
Hunter
syndrome, also known as
Mucopolysaccharidosis II is a rare X-linked recessive disorder caused by
deficiency of the lysosomal enzyme iduronate sulfatase, leading to progressive
accumulation of glycosaminoglycans in nearly all cell types, tissues, and
organs. Mutations in the IDS gene cause MPS II. The IDS gene provides
instructions for producing the I2S enzyme, which is involved in the breakdown
of large sugar molecules called glycosaminoglycans (GAGs).
Two relatively distinct clinical forms of MPS II have been recognized
i.e., the non-neuronopathic form (formerly defined as slowly progressive milder
form) of the disease, intelligence may be normal or only slightly impaired and
neuronopathic form of the disease (formerly called early progressive more
severe form), intellectual disabilities may be apparent in the early life of
the patient.
Epidemiology- Thelansis estimates MPS II typically affects only males,
with symptoms becoming apparent at approximately 2-4 years of age. The disorder
occurs in approximately 1 in 100,000 to 1 in 170,000 male births.
Competitive landscape of Hunter syndrome (Mucopolysaccharidosis Type II)
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
KOLs insights of Hunter syndrome (Mucopolysaccharidosis Type II) across
8 MM market from center of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm and Unmet needs.
Hunter syndrome (Mucopolysaccharidosis Type II) Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs
with sourcing, Market Event and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden and pricing scenario, Summary and Insights.
Asset Company Stage
iduronate-2-sulfatase, Green Cross
GC Pharma Launched
idursulfase Takeda Launched
JR-141 JCR
Pharmaceuticals Phase III
AGT-182 ArmaGen Phase II
idursulfase-beta (sc), Green Cross
GC Pharma Phase II
RGX-121 REGENXBIO Phase II
SB-913 Sangamo
Therapeutics Phase II
odiparcil, Inventiva
Inventiva Phase II
DNL-310 Denali
Therapeutics Pre-clinical
EGT-301 Esteve Pre-clinical
Mucopolysaccharidosis type II therapy, Immusoft Immusoft Pre-clinical
No comments:
Post a Comment